Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (221-230 of 388) with videos related to

Pageof 39
Sort By:
Clinical Colorectal Cancer|March 22, 2024
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal CancerLaura Roazzi, Giorgio Patelli, Katia Bruna Bencardino, et al.
Clinical Genitourinary Cancer|December 2, 2020
Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United StatesMatteo Santoni, Francesco Piva, Camillo Porta, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2011
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinomaCamillo Porta, Susanne Osanto, Alain Ravaud, et al.
Critical Reviews in Oncology/Hematology|September 8, 2014
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysisEmilio Bria, Francesco Massari, Francesca Maines, et al.
Cancer|June 16, 2010
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factorsRobert J Motzer, Bernard Escudier, Stephane Oudard, et al.
Oncoimmunology|November 12, 2020
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisionsLorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Critical Reviews in Oncology/Hematology|August 12, 2019
Toward a genome-based treatment landscape for renal cell carcinomaFrancesco Massari, Vincenzo Di Nunno, Matteo Santoni, et al.
Clinical Genitourinary Cancer|May 6, 2014
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicityJoaquim Bellmunt, Francesc Pons, Abigail Foreshew, et al.
The Oncologist|January 23, 2024
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 TrialKathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, et al.
Clinical Genitourinary Cancer|January 15, 2015
Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the LiteratureVittorio Fusco, Camillo Porta, Giorgia Saia, et al.
Pageof 39

Showing results (221-230 of 388) with videos related to

Sort By:
Pageof 39
Clinical Colorectal Cancer|March 22, 2024
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal CancerLaura Roazzi, Giorgio Patelli, Katia Bruna Bencardino, et al.
Clinical Genitourinary Cancer|December 2, 2020
Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United StatesMatteo Santoni, Francesco Piva, Camillo Porta, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2011
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinomaCamillo Porta, Susanne Osanto, Alain Ravaud, et al.
Critical Reviews in Oncology/Hematology|September 8, 2014
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysisEmilio Bria, Francesco Massari, Francesca Maines, et al.
Cancer|June 16, 2010
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factorsRobert J Motzer, Bernard Escudier, Stephane Oudard, et al.
Oncoimmunology|November 12, 2020
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisionsLorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Critical Reviews in Oncology/Hematology|August 12, 2019
Toward a genome-based treatment landscape for renal cell carcinomaFrancesco Massari, Vincenzo Di Nunno, Matteo Santoni, et al.
Clinical Genitourinary Cancer|May 6, 2014
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicityJoaquim Bellmunt, Francesc Pons, Abigail Foreshew, et al.
The Oncologist|January 23, 2024
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 TrialKathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, et al.
Clinical Genitourinary Cancer|January 15, 2015
Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the LiteratureVittorio Fusco, Camillo Porta, Giorgia Saia, et al.
Pageof 39